✦ LIBER ✦

Influence of the matrix composition in the emission spectroscopic analysis of solutions with continuous nebulization of the sample and excitation of the spectrum in a high-frequency inductively coupled plasma discharge

✍ Scribed by Kh. I. Zil'bershtein; M. A. Kartasheva; G. N. Moshkovich

Publisher: Springer US
Year: 1986
Tongue: English
Weight: 361 KB
Volume: 44
Category: Article
ISSN: 0021-9037
DOI: 10.1007/bf00661040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Emission spectral analysis of microvolum

Emission spectral analysis of microvolumes of solutions with the use of high-frequency inductively coupled plasma discharge

✍ Kh. I. Zil'bershtein; M. A. Kartasheva; G. N. Moshkovich 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 363 KB

Investigation and optimization of the pa

Investigation and optimization of the parameters of a setup with a high-frequency inductively coupled plasma for emission spectral analysis of solutions

✍ Kh. I. Zil'bershtein; M. A. Kartashova; G. N. Moshkovich; G. P. Startsev 📂 Article 📅 1982 🏛 Springer US 🌐 English ⚖ 736 KB

Peculiarities in the spectroscopic deter

Peculiarities in the spectroscopic determination of the isotopic composition of hydrogen in a plasma high-frequency discharge at low and medium pressures

✍ V. M. Nemets; A. A. Petrov; A. A. Solov'ev 📂 Article 📅 1981 🏛 Springer US 🌐 English ⚖ 529 KB

Quantitative analysis of the novel antic

Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry

✍ E. Stokvis; H. Rosing; M. Crul; M. J. Rieser; A. J. R. Heck; J. H. M. Schellens; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB 👁 2 views

## Abstract A liquid chromatographic/tandem mass spectrometric (LC/MS/MS) assay for the quantitative analysis of the novel anticancer drug ABT‐518 and the screening of six potential metabolites in human plasma has been developed and validated to support a phase I study with the drug. ABT‐518 is an